2.40
+0.04
(1.48%)
May 21 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 2.28 - 2.46 |
| 52 week | 1.99 - 4.00 |
| Open | 2.36 |
| Vol / Avg. | 136,215.00/123,613.00 |
| Mkt cap | 91.22M |
| P/E | - |
| Div/yield | - |
| EPS | -0.88 |
| Shares | 38.01M |
| Beta | 1.93 |
| Inst. own | 51% |
Events
May 20, 2013
Codexis, Inc. at UBS Global Healthcare Conference -
May 7, 2013
Q1 2013 Codexis, Inc. Earnings Conference Call -
Feb 27, 2013
Q4 2012 Codexis, Inc. Earnings Conference Call -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -83.82% | -34.95% |
| Operating margin | -83.88% | -34.56% |
| EBITD margin | - | -20.49% |
| Return on average assets | -39.87% | -26.16% |
| Return on average equity | -51.74% | -34.07% |
| Employees | 154 | - |
| Carbon Disclosure Rating | - | - |
Address
200 Penobscot Drive
REDWOOD CITY, CA 94063
United States - Map
+1-650-4218100 (Phone)
+1-302-6555049 (Fax)
REDWOOD CITY, CA 94063
United States - Map
+1-650-4218100 (Phone)
+1-302-6555049 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Codexis, Inc. provides biocatalyst and fermentation processes and products. The Company provides its customers research and development services, biocatalysts and fermentation strains, synthetic and natural products. It is a subsidiary of publicly-traded Maxygen. Codexis uses the Molecular Breeding platform to develop enzymes and fermentation strains. These biocatalysts are designed for specific commercial applications, and various manufacturing processes.
Officers and directors
| Thomas R. Baruch JD | Independent Chairman of the Board | |
| John J. Nicols | President, Chief Executive Officer, Director | |
| David D. O'Toole CPA | Chief Financial Officer, Senior Vice President, Principal Accounting Officer | |
| Douglas T Sheehy JD | Senior Vice President, General Counsel, Secretary | |
| David L. Anton Ph.D. | Senior Vice President - BioIndustrials | |
| Mark Ho | Interim Controller | |
| Alexander A. Karsner | Director | |
| Pedro Isamu Mizutani | Director | |
| Byron L. Dorgan | Independent Director | |
| Bernard J. Kelley | Independent Director |